RICHMOND, Va., Dec. 8, 2020 /PRNewswire/ — BRAINBox Solutions today announced the initial closing on a $23 million Series A financing to support the clinical development of the company’s BRAINBox TBI (Traumatic Brain Injury) Test to aid both in the diagnosis and prognosis of mild TBI (concussion). BioVentures Investors led the financing round and was joined by the Tauber Foundation, the Virginia Tech Carilion Innovation and Seed Funds, Genoa VC, Pharmakon Holdings LLC, Astia Angels and additional qualified investors, including Kevin Love, professional basketball player and mental health advocate. 

“The BRAINBox TBI test has enormous potential to significantly improve patient care as an aid to objectively diagnosing and managing the treatment of concussion patients,” said Marc Goldberg, BioVentures Investors Co-Founder and Managing Partner. “The company has made great progress, particularly in this challenging COVID-19 environment, in advancing the development of the BRAINBox TBI testing system, including laying the groundwork for the pivotal, HeadSMART II clinical trial and securing ‘Breakthrough Designation’ from the FDA.”  He noted there are more than five million patients evaluated in emergency rooms annually for mild TBI as well as additional patients in urgent care settings.

Bob Sledd, a BRAINBox Director and immediate past chairman of the board of Owens & Minor, added, “With this funding, the company is well positioned to take the key future steps necessary for a FDA regulatory filing for product approval and  commercialization.”

Read the full article at: www.prnewswire.com

The following two tabs change content below.

• Bio
• Latest Posts

Chris Frew

President, CEO at Biobuzz Media & Workforce Genetics

Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

Latest posts by Chris Frew (see all)

• Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study - November 2, 2021
• Children’s National’s Dr. Kurt Newman Named WBJ’s 2021 CEO of the Year - October 26, 2021
• SciNeuro Pharmaceuticals and Mabylon AG to Collaborate on Development of Novel Therapeutics for Neurological Diseases | Business Wire - October 26, 2021
• Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company | Business Wire - October 21, 2021
• D&D Pharmatech Raises $51M in Series C Financing to Advance Phase 2 Clinical Trials for Neurodegenerative, Fibrotic, and Metabolic Diseases - October 19, 2021